School childrens becoming drug addicts

Mumbai

Maharashtra Food and Drug Administration (FDA) recently seized 15,000 bottles of codeine containing cough syrups of leading brands  from the open market of Kashimira area of Thane district . It was observed that these illegal cough syrups were being sold at an exorbitant cost without a valid license. Stocks of brands like Rexcof manufactured by Cipla Ltd and Corex manufactured by Pfizer Ltd were seized among others during the FDA raid. All this clandestine activity was based on illegal purchases, without a license. These stocks were planned to be sold to drug addicts at a very high price. This is the first such case detected in the recent months involving distribution of a formulation  containing huge quantities  narcotic drug codeine phosphate, according to a senior FDA official. These cough syrups also included the Reskop  manufactured by Promed Laboratories Pvt Ltd, Indore, Rancodex manufactured by Smilax Healthcare Pvt Ltd, Baddi and marketed by Ranbaxy Laboratory Ltd and Conex manufactured by Acron Pharmaceuticals, Ahmedabad.Cough syrups worth over Rs 15 lakhs were seized from two persons from Thane in contravention to the provisions of Drugs and Cosmetics Act, 1940. One person has been arrested by Kashimira police under the charges of 18A, 18C of Drugs and Cosmetics Act and sections 328, 336, 269, 36 of IPC. Police is in search of another person who is believed to be involved in this racket. Maharashtra FDA had also alerted Pharma companies like Pfizer, Cipla and Lupin in the past to keep a check on the distribution channels to address its illegal sale to drug addicts.Investigations have revealed that drug dealers selling these medicines are scattered across Madhya Pradesh and Gujarat from where these drugs are sourced out and distributed in Maharashtra through illegal distribution channels. These drugs are manufactured by around 20 companies in Himachal Pradesh, Dehradun and Jammu and Kashmir.The raid was carried by the intelligence branch of FDA Maharashtra based on a tip off that there are some  drug addicts and school  children, who had become drug addicts. On the orders of FDA commissioner, Dr. Harshadeep Kamble based on a tip, the team of intelligence branch headed by O S Sadhwani, joint commissioner (IB), kept a watch on the entire operation. The exercise confirmed about the supply of these drugs from an unidentified source following which a trap was laid at Kashimira region of Thane district.
  • Related Posts

    NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

    The officials identified the substance as Alprazolam manufactured illegally at the lab. HYDERABAD: In one of the largest such seizures in recent times, the Narcotics Control Bureau (NCB), Hyderabad, raided…

    Govt Outlines AYUSH Heavy Metal Monitoring Steps In Rajya Sabha

    New Delhi: The Ministry of AYUSH has detailed its regulatory framework and ongoing initiatives to monitor heavy metal content in traditional medicines, responding to parliamentary concerns over quality and safety…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Commissioner FDA reviews enforcement measures

    Commissioner FDA reviews enforcement measures

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Karnataka High Court stays FSSAI advisory banning use of Ashwagandha leaves in health supplements

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    Roche Pharma launches Tecentriq® SC, India’s first subcutaneous immunotherapy for lung cancer

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    CDSCO tighten drug quality oversight as substandard and spurious medicine cases rise in five years

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Piramal Pharma Gets 3 USFDA Observations at US Facility

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices

    Eli Lilly pauses Indian obesity awareness campaign after regulatory notices